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The roles of chemokine receptor V (CCR5) and its polymorphism, rs333 in multiple sclerosis
(MS) are controversial. We investigated the receptor and its deletion in a large MS (428) and
a numerous control (831) population in Csongrád County  (Hungary) and North-Bácska
(Serbia). Taqman probes firstly  were used for the allele discrimination. There was no
significant difference  in genotype  (OR=1.092, 95%  CI=0.807-1.478, p=0.568 for wt/wt
(wt=wild type  allele) vs wt/Δ32, Δ32/Δ32 (∆32=∆32  base  pair deletion allele))  or  allele
frequency (OR=0.914, 95% CI=0.692-1.207, p=0,525). Neither the deletion nor the wt allele
affected the Expanded Disability Status Scale score or the age at onset. Our results indicate no
association between the CCR5 ∆32 allele and MS.
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CNS: central nervous system
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Multiple sclerosis (MS) is an autoimmune neurodegenerative disease of  the  central nervous
system (CNS), which appears mostly in the young adult population. The disease affects 2.5
million people worldwide. The lifetime risk is 1 in 400 [1], which makes MS potentially the
most common cause of neurological disability in young adults. The aetiology of the disease is
only  partially known; a genetic predisposition plays a clear role, acting together with
unidentified environmental factors and autoimmune inflammatory mechanisms.
Despite  the  evidence  of  a  genetic  background  [2-4],  only  the  major  histocompatibility
complex (MHC) has been identified as a definite susceptibility factor both in case-control and
in family-based studies [5-7]. However, the MHC locus is associated not only with MS, but
also with other  autoimmune diseases. Identification of the risk and protective factors has
therefore been at the focus of MS research.
It is well known that the CNS inflammation in MS is characterized by  myelin loss, axonal
damage and gliosis,  and results  in  progressive neurological  dysfunctions.  The chemokines
(chemoattractant cytokines) and chemokine receptors play  key  roles in inflammatory
processes,  because  they  control  the  migration  of  the  immune  cells  and  can  direct  the
migration of T-cells across the blood-brain barrier, which is probably the first step towards
the development of MS.
The chemokine  receptor  V (CCR5),  a member  of the chemokine  receptor  family and  a
receptor for  MIP-1ɑ/CCL3, MIP-1β/CCL4 and RANTES/CCL5, is at the focus of genetic
investigations in MS. The results of a number of studies have indicated that the receptor is
upregulated within inflamed brain regions in samples from human MS patients [8-10] and in
animal models of experimental autoimmune encephalomyelitis [11, 12]. The CCR5 gene (also
known as CKR5, CCR-5, CD195, CKR-5, CCCKR5, CMKBR5, IDDM22 and CC-CKR-5),
located in the 3p21.31 chromosome region [13], consists of 4 exons and 2 introns. It encodes
a  352 amino acid protein with a  calculated molecular  mass of  a  40.6 Da. Two different
promoters have been found upstream and downstream of exon 1 [14]. Two transcript variants
encoding the same protein have been identified. The structure of the protein consists of 7
transmembrane hydrophobic ɑ-helices, an intracellular carboxyl terminus and an extracellular
amino terminus with a  potential N-linked glycosylation site [15] and because  of  this
conformation  it  belongs  in  the G-protein  coupled  receptor  family.  The  CCR5  is  mainly
expressed  in  memory  and  effector  T-lymphocytes,  monocytes,  macrophages,  immature
dendritic cells and NK cells, in which it controls cell activation and chemotaxis [16, 17]. In
the CNS, the receptor is found on neurones, astrocytes and microglia [15, 18]. The possible
interactions and functions of the protein in the CNS were recently reviewed [19].
A single nucleotide polymorphism (SNP) can influence the protein function. The most widely
investigated polymorphism of the CCR5 gene is a 32 base pair (bp) deletion, which causes a
frame shift mutation in exon 1, thereby  affording protection against HIV infection in
homozygotic form and resulting  in a slower progression and decreased viral load in
heterozygotic form [20-22]. This deletion results in a truncated protein (215 vs 352 amino
acids), which excludes membrane insertion of the malfunctioining protein [13, 19, 23]. The
HIV  virus  therefore cannot  penetrate into  the  host  cells,  with  the consequence that  this
deletion provides protection for homozygous individuals.
Investigations of the ∆32 bp deletion in MS samples and controls have revealed  conflicting
results. In some studies, the allele was concluded to be a risk factor for MS [24-27], whereas
in others it seemed to be a protective factor [28-31], and there are results indicating that this
mutation is neither a risk nor a protective factor in the case of MS [32-36] (reviewed in Table
4). There have been numerous investigations of the roles of the CCR5 gene and the ∆32
mutation in MS, but only a few which involved large MS and control samples, so our aim was
to check their role in a larger MS and almost the biggest control population.
In view of the increasing incidence of MS in Europe and the lack of data regarding the genetic 
background of the ∆32 allele in the populations of Csongrád County (Hungary) and North- 
Bácska (Serbia), this study was conducted to determine the influence of the ∆32 deletion in 
the CCR5 gene in MS patients and healthy controls in these regions.
2.1. MS Patients and Controls
All study participants gave their written informed consent. 428 unrelated clinically definitive
MS patients with the relapsing/remitting (RR) or secondary progressive (SP) form of the
disease and 831 healthy  controls from Csongrád County, Hungary, and the North-Bácska
region in Serbia  were enrolled to investigate the possible effects of the CCR5 ∆32 deletion.
The patients and volunteer controls were enrolled at the Department of Neurology, Faculty of
Medicine, University of Szeged, Hungary, the Institute of Preventive Medicine, Faculty of
Public Health, University of Debrecen, Hungary, and the Department of Neurology, Subotica
Hospital, Subotica, Serbia. Demographic data were collected by means of a questionnaire. All
the MS patients in this study met the McDonald criteria and had clinically definitive MS with
the RR or SP form [37]. The patient and control groups did not differ from each other in sex
ratio (p=0.942) or mean age (p=0.414). The MS patient group comprised 106 males and 322
females; their average age was 43.74±11.97 years, their average age at the onset of the disease
was 32.17±9.80 years and the average Expanded Disability Status Scale (EDSS) score was
2.54±1.92. The MS group consisted of 377 RR patients (91 males and 286 females, average
age  42.56±11.70  years)  and  51  SP  patients  (15  males  and  36  females,  average  age
52.49±10.35 years). Of the 831 controls, 204 were  males and 626 were females, with an
average age of 44.34±13.20 years. The general sociodemographic data are to be seen in
Tables 1 and 2. The study  protocol was approved by the Medical Research Committee on
Science and Research Ethics (No, 35764/2012/EKU (566/PI12)) and was in accordance with
the Helsinki Declaration.
In the cases of 3 control samples from Debrecen, there was insufficient DNA sample for the 
allele discrimination protocol, and for 1 sample the gender information was missing.
2.2.1. DNA isolation
Peripheral blood was used to isolate genomic DNA by a standard desalting method [38]. The
purified DNA was stored at -20 °C until further use, while the remaining of the whole blood
was stored at -80 °C at the biobank of the Department of Neurology, Faculty of Medicine,
University of  Szeged  (biobank  licence:  135/2008).  Some  of  the  control  samples  (DNA)
originated from the biobank in Debrecen, where  samples are  collected from throughout
Hungary. Patients and control samples from Subotica, Serbia, were  included within the
Hungarian-Serbian cooperation programme (HUSRB/1002/214/082/01), which is supported
by the EU.
2.2.2. Polymerase chain reaction (PCR) with Taqman probes
For   the   first   time   fluorescently  labelled   Taqman   probes   were   used   for   the   allele
discrimination; not only is this technique faster than the standard PCR and gel electrophoresis
methods, but less hazardous waste is generated and it is safer, because it does not require
ethidium bromide or other intercalating dye. As compared with DNA chip experiments, it is
much cheaper, but only one SNP can be investigated, in contrast with DNA chips.
For the amplification of the DNA region near the rs333 SNP, the following primers were
used: forward primer: 5’-AAG AAG GTC TTC ATT ACA CC-3’, reverse primer: 5’-AGC
AGA GTT TTT AGG ATT CC-3’. For the allele discrimination, the following  probes were
applied: the wild-type allele: 5’-Fam-CAT ACA GTC AGT ATC AAT TCT GGA A-BHQ-1-
3’, and the deletion allele: 5’-Hex-CTC TCA TTT TCC ATA CAT TAA AGA TAG-BHQ-1-
3’.
The PCR amplification was carried out with the following parameters: 95 °C for  3 min,
followed by 49 cycles of 95 °C for 10 s, and then 59 °C for 50 s. A genotyping specific
master  mix was used (PCR Biosystem 2x PCR Bio Gentyping mix Lo-ROX). The  PCR
experiments were performed with a BioRad CFX96 C1000 real-time thermal cycler machine,
and the genotype analysis was carried out with BioRad software  (BioRad CFX Manager
version 1.6). The results were checked by agarose gel electrophoresis, with exactly the same
outcome (bands at 154 bp for the wild types, at 154 and 122 bp for the heterozygotes, and at
122 bp for the homozygotes).
2.2.3. Statistical methods
For evaluation of the data, SPSS software  version 20.0 was used. The Chi-square test was
utilized for  the comparison of  the  distribution of genotypes and alleles, the t-test for the
comparison of the averages of two groups, variance  analysis in the event of more than two
groups, and two-way variance analysis when there were more than two grouping criteria.
The observed genotype frequencies were in accordance with the Hardy-Weinberg equilibrium
(HWE) in both the MS and the control groups.
Of the 428 MS patients, 352 were wild type, 71 were heterozygous and 5 were homozygous 
for the ∆32 deletion. The ∆32 allele frequency was 9.46%. Among the control samples, 670 
were wild type, 146 were heterozygous and 12 were homozygous for the deletion, and the minor
allele frequency for this group was 10.26%. The distributions of the genotype and allele 
frequencies of the CCR5 rs333 polymorphism in the MS patients and the controls are given in 
Table 3. There was no significant difference between the MS patients and the healthy controls in
either the genotype (OR=1.092, 95% CI=0.807-1.478, p=0.568 for wt/wt vs wt/Δ32, Δ32/Δ32)  
or  the  allele  frequencies  (OR=0.914,  95%  CI=0.692-1.207,  p=0.525).  No significant  
association  was found between  the rs333 polymorphism  and the EDSS score (F=0.282; 
p=0.755) or the age at onset (F=0.416; p=0.660). Neither the deletion nor the wild- type allele 
affected the EDSS score (wt allele: F=0.032, p=0.858; ∆32 allele: F=0.564; p=0.453) or the age 
at onset of the disease (wt allele: F=0.010, p=0.921; ∆32 allele: F=0.821, p=0.365). Not only the
genetic predisposition, but also the environmental factors can have a crucial impact on the 
development of MS. To investigate these effects jointly, the combined influence of the wild type
or the deletion allele with alcohol consumption, smoking and body mass index (BMI) was 
examined in the MS patients, but none of these combinations proved to be significant in 
relation to the EDSS score or the age at onset. Our results indicate a lack of an association 
between the CCR5 ∆32 allele and the risk of MS in the Csongrád County (Hungary) and North-
Bácska (Serbia) population.
This study investigated the role of the CCR5 ∆32 deletion in a large number of MS patients
and the second biggest control population in Csongrád County (Hungary) and North-Bácska
(Serbia).  This  population  has  not  been  involved  in  CCR5  trials  previously.  The  results
indicate the lack of  an association between the CCR5 ∆32 allele  and the risk of MS. These
findings are  consistent with data from several other  studies [32-36, 39-41]. In contrast, a
number of previous investigations have concluded that this mutation is a protective factor [28,
30, 31, 42-47] (Table 4). These studies include only one case in which the deletion allele was
more common in the control population, as a strong indication of the protection [43]. In the
vast majority of the articles, the protection was reflected by the higher age at the onset of the
disease [28, 42, 45, 46], by the lower severity [29, 47] or by the better MRI results [30, 31,
44].  The  lack  or  weakness  of  protection  associated  with  the  CCR5  ∆32  deletion  allele
suggests that the CCR5 receptor does not play an important role in the context of migration of
the immune cells into the CNS in MS. However, it is important that the CCR5 ∆32 allele has
been suggested to be a risk factor in MS [24-27]. The contradictory results may be due to the
inadequate selection of the control or patient groups [26] or both  [27]. In those studies, the
genotype distribution did not correspond with the HWE. In an investigation of 89 MS patients
and 119 controls [26],  71 of the MS patients were wild-type homozygotes, 12 were
heterozygotes and 6 were homozygotes for the deletion, while 88 of the controls were wild-
type homozygotes, 30 were heterozygotes and 1 was homozygous for the deletion. The result
of the HWE test for the patient group was χ
2
=15.85, p=0.000068; as the p value was <0.05,
the group was not consistent with the HWE, the selected group did not adequately represent 
the population. In the control group, there was one category (homozygous deletion) with less 
than 5 members, which means that the value is not accurate (χ2=0.822, p=0.364). In the 
Iranian population 254  MS patients and 380 controls were analysed  [27]. The genotype
distribution in the MS  group was  201 wild-type homozygotes, 16 heterozygotes and  37
homozygous for the deletion. In the control group, the corresponding numbers were 323, 49
and  8,  respectively.  The  result  of  the  HWE  test  for  the  MS  group  was  χ2=156.100,
p<0.000001 and that for the control group was χ2=11.724, p<0.001, so neither the MS nor the
control group corresponded with the HWE. In another study, no significant difference in
allele frequency or genotype prevalence was observed between the patient and control groups
and the allele did not influence the age  at onset of the disease [24]. Further investigations
revealed that MS patients who carried the deletion died 8.44 years earlier on average. These
observations were more significant in females, and the authors concluded that the deletion
might serve as a prognostic marker for MS. However, the control group was not studied, and
the possibility  remains that the allele has a similar effect in healthy  controls too. Different
results emerged from two studies by one group of authors [42, 48]. In the earlier paper, they
concluded that the allele is a protective factor because (CCR5∆32, DR4) positive phenotype
was negatively associated with an early MS onset [42], whereas they later identified a two-
allelic combination which is MS associated [48]. The explanation of these different results on
the overlapping populations may lie in the difference in the statistical methods used or in the
studied MS subtypes. There has been only one article in which the allele was associated with
the PP MS subtype, but the number of PP MS patients was only 30, and this outcome should
therefore be checked on larger groups. The PP MS subtype is a different entity from the
RR/SP MS subtypes, and it is perhaps best to disregard the PP MS results in a consideration
of the RR/SP MS subtypes.
Overall, it appears likely that this receptor does not influence the migration of the immune 
cells into the CNS in MS in general or other receptors can take over this function. It has only a
small effect; if the receptor is not functioning (homozygous ∆32 bp deletion), the results 
indicate only a slight protection or ineffectiveness.
Identification of the main receptor that controls the entry of the immune cells into the CNS in
MS is an important question for the pathomechanism and for the pharmaceutical industry.
Revealing the main mechanism and the details of the direction of the migration of the immune
cells into the CNS are undoubtedly important in the future MS research.
To summarize the results, it seems very likely that the CCR5 receptor has only a weak role in 
MS. This study has not identified any association of the ∆32 deletion of the CCR5 gene and 
MS. Our results with a large number of MS patients and the second biggest control population 
confirm a recently published study which examined the largest MS and control population 
(Song and Lee 2013).
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Table 1
Sociodemographic data in the two examined groupsMales Females Mean age (SD) EDSS score Age at onset (SD)
Group (n)
(%) (%) (years) (SD) (years)
MS patients
(428)
106
(24.8)
322
(75.2)
43.74±11.97        2.54±1.92            32.17±9.80
Controls
(831)
204
(24.6)
626
(75.4)
44.34±13.20                -                           -
Abbreviations: EDSS = Expanded Disability Status Scale, SD = standard deviation
Sociodemographic data in the two examined MS subgroupsMales Females Mean age (SD) EDSS score (SD) Age at onset
Group (n)
(%) (%) (years) (years) (SD) (years)
RR (377)    91 (24.1)    286 (75.09)      42.56±11.70            2.09±1.52              32.07±9.58
SP (51)      15 (29.4)      36 (70.6)        52.49±10.35            5.87±1.20             32.92±11.32
Abbreviations: EDSS = Expanded Disability Status Scale, SD = standard deviation, RR =
relapsing/remitting multiple sclerosis, SP = secondary progressive multiple sclerosis
Genotype and allele frequencies of CCR5 rs333 polymorphism+/+ +/∆32 ∆32/∆32 + ∆32
Group (n)
(%) (%) (%) (%) (%)
MS patients
(428)
352 (82.2)      71 (16.6)             5 (1.2)           775 (90.53)            81 (9.46)
Controls
(828)
670 (81.4)     146 (17.6)           12 (1.4)
1486
(89.73)
170 (10.26)
Abbreviations: +/+ = wild type, +/∆32 = heterozygote, ∆32/∆32 = homozygote, + = wild-type
allele, ∆32 = deletion allele
Table 4
Summary of the most important results about CCR5 and MS
MS patients
(% women)
Controls
(% women)Population Results Reference
sporadic 299
(~71%)
Age at onset approximately 3 years higher in patients 
carrying the
deletion
USA (II), Americans [28]
index cases
120 (~75%)
Ag  at onset approximately 3 years higher in patients 
carrying the
deletion
USA (I), Americans [28]
Australian 120 No significant difference in 
allele or genotype frequencies
[39]
Presence 
of the 
allele 
Italian (Sicilian) 180 (73%) [29]
(CCR5∆3
2, DR4) 
positive 
Russian 219 (57%) [42]
Russian overlaps with
Favorova et al, 2002
362
(43.9%)286 (61.5%) Two-allelic combination associated with MS 
[48]
USA, Americans 132 (64%) Associated with early death 
(the effect more significant in 
[24]
CCR5 
deletion 
allele 
Finnish 116 (57.7%) [25]
USA, overlaps with 
Barcellos et al, 2000, 
Americans
421 96 No significant difference in 
allele or genotype 
[33]
Deletion 
more 
frequent in
Spanish (other origins) 102 [43]
Deletion 
more Spanish (Basque) 62 [43]
Population                              
MS patients
(% women)
Finnish, overlaps with
Controls
(% women)
Results                                                                                                     Reference
Increased frequency of ∆32/∆32 among all MS patients; the ∆32/∆32
Luomala et al, 2003               
89                      119
genotype increased in the PP MS group                                                  
[26]
Croatian and Slovenian         325 (71%)         356               No significant difference in allele or genotype frequencies                    [34]Danish, overlaps with
Sellebjerg et al, 2007
70                      0                   CCR5∆32 shows a trend towards a smaller lesion burden                      [44]
Danish                                    148 (73%)         151               
Age at onset lower in patients (who have intrathecal synthesis of IgG
oligoclonal band) carrying the deletions
CCR5∆32 allele not associated with attack risk in patients treated
[45]
Danish                                    109 (75%)         105 (70%) with IFN-β; patients had higher percentage of CCR5-positive
monocytes than controls
[49]
Irish                                        439                    230               
The population-based RR/SP MS group was associated with lower
age at disease onset
CCR5+303*G and ∆32 low T1 lesion volume, CCR5∆32 low black
[46]
Dutch, The Netherlands         637 (66%)         177 (54%) hole ratio (T1/T2 lesion volumes), CCR5∆32 high percentage
remyelinating lesions
[30]
USA, African Americans      442                    293               No significant difference in allele or genotype frequencies                    [35]
Iranian                                    254 (83.46%)    380               
∆32 allele more frequent among patients; ∆32/∆32 genotype higher
in patients than in controls; might be a risk factor [27]
Brazilian                                124 (68.5%)      
127 
(44.1%)
Israelian                                 256                    0
German                                  253                    0
MS patients with ∆32 allele gave a lower positive gadolinium-
enhancing imaging
Progression to disability prolonged in CCR5∆32 homozygotes and
heterozygotes compared with MS patients with the wild-type 
genotype
No difference in age, sex, EDSS score, disease duration between 
patients carrying or non-carring the allele; no correlation between
CCR5∆32 and G-protein β3 subunit 825T polymorphism
[31]
[47]
[40]
German                                  221 (71.04%)    0                   
No association with disease severity, age at onset, gender or disease
course
[41]
MS patients
(% women)
Controls
(% women)Population Results Reference
94 brain
biopsy patients (83
MS)German 0 [41]
Europeans 1666 2
2
No association with disease or disease 
subtypes
[36]
Iranian 100 3
0
No association [32]
